A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation

D.H. Lee; A. Roohullah; B.C. Cho; S-H. Lee; C. Lemech; P. de Souza; M. Millward; J. Choi; K.E. Park; E. Kim; N.Y. Kim; Y.K. Shin; J-Y. Han

doi:10.1016/j.annonc.2022.07.1320

YUHSpace

BROWSE

0 178

Cited 0 times in

A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation

Authors: D.H. Lee ; A. Roohullah ; B.C. Cho ; S-H. Lee ; C. Lemech ; P. de Souza ; M. Millward ; J. Choi ; K.E. Park ; E. Kim ; N.Y. Kim ; Y.K. Shin ; J-Y. Han